Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Type: Oral Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies:...
Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL)
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Type: Oral Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell...
NOVINKY Z ASH® – AGRESÍVNE LYMFÓMY
11 septembra, 2020 7:51 pmV plenárnej sekcii boli prezentované výsledky štúdie fázy 1/1b GO2971, skúmajúcej bezpečnosť a účinnosť mosunetuzumabu v liečbe pacientov s relabovaným alebo refraktérnym difúznym veľkobunkovým...
Treatment of Adults with Relapsed/Refractory Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study
11 septembra, 2020 7:51 pmProgram Oral and Poster Abstracts Session 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster II Hematology Disease Topics...
Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadolin Study
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster II ...
Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Type: Oral Session: 642. CLL: Therapy, excluding Transplantation: First Line Treatment Hematology...
Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Type: Oral Session: 642. CLL: Therapy, excluding Transplantation: First Line Treatment Hematology...
ASH® 2019 – B-CLL a indolentné lymfómy
11 septembra, 2020 7:51 pm61. výročná konferencia ASH priniesla zaujímavé novinky a diskusie aj v oblasti indolentných lymfoproliferácií – indolentných lymfómov (iNHL) a chronickej lymfocytovej leukémie (CLL)....
ITP v těhotenství
11 septembra, 2020 5:52 pmLéčba ITP během těhotenství Na ITP v těhotenství se zaměřila MUDr. Jacqueline Soukupová Maaloufová z Ústavu hematologie a krevní...
Zkušenosti s léčbou agonisty TPO receptoru u dětí
11 septembra, 2020 5:52 pmPraxe potvrzuje účinnost léčby pomocí TPO-RA u dětí MUDr. Petr Smíšek z Kliniky dětské hematologie a onkologie 2. LF UK a FN Motol (KDHO),...